Lord, Abbett & Co
ADAP

Lord, Abbett & Co’s Adaptimmune Therapeutics ADAP Stock Holding History

Lord, Abbett & Co’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-466,668
Closed -$2.52M – 630
2020
Q4 		$2.52M Sell
466,668
-16,504
-3% -$89.7K 0.01% 623
2020
Q3 		$3.86M Sell
483,172
-24,349
-5% -$213K 0.01% 588
2020
Q2 		$5.08M Buy
+507,521
New +$3.19M 0.02% 568
2015
Q4 		– Sell
-111,094
Closed -$1.33M – 875
2015
Q3 		$1.33M Sell
111,094
-138,439
-55% -$1.96M ﹤0.01% 872
2015
Q2 		$4.57M Buy
+249,533
New +$4.28M 0.01% 789

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Lord, Abbett & Co's ADAP Position: Q1 2021 in Review

Lord, Abbett & Co sold out of Adaptimmune Therapeutics (ADAP) in Q1 2021, closing a stake of 466,668 shares — an estimated $2.52M sold.

Lord, Abbett & Co first reported a position in ADAP in Q2 2015 and held it in 5 quarters. The position peaked at $5.08M in Q2 2020. 84 funds tracked by Wall St. Rank hold ADAP as of Q1 2021.

  • Lord, Abbett & Co reported no remaining Adaptimmune Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Lord, Abbett & Co sold 466,668 Adaptimmune Therapeutics shares in Q1 2021, an estimated $2.52M.
  • Lord, Abbett & Co first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 5 quarters.
  • Lord, Abbett & Co's Adaptimmune Therapeutics position peaked at $5.08M in Q2 2020.
  • 84 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2021.

Based on Lord, Abbett & Co's 13F filing for Q1 2021, filed 11 May 2021.